Sleep Disorder and Cardiovascular Risk Factors among Patients with Type 2 Diabetes Mellitus by Shim, Unjin et al.
ORIGINAL ARTICLE
korean j intern med 2011;26:277-284
http://dx.doi.org/10.3904/kjim.2011.26.3.277 
pISSN 1226-3303    eISSN 2005-6648
http://www.kjim.or.kr
Sleep Disorder and Cardiovascular Risk Factors among 
Patients with Type 2 Diabetes Mellitus
Unjin Shim, Hyejin Lee, Jee-Young Oh, and Yeon-Ah Sung
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea
Background/Aims: Sleep disorder (SD) is associated with an increased risk of cardiovascular disease and is more 
prevalent among individuals with type 2 diabetes mellitus. These health problems not only frequently coexist but also 
exacerbate each other. We conducted a cross-sectional study to estimate the prevalence of SD among diabetic patients 
and to investigate the relationship between SD and cardiovascular risk among these patients.
Methods: We recruited 784 patients with type 2 diabetes and conducted a self-administered questionnaire. We assessed 
sleep quality using the Pittsburgh Sleep Quality Index and the risk of obstructive sleep apnea (OSA) using the Berlin 
Questionnaire. Additional information included blood pressure and metabolic profiles.
Results: Of the 784 diabetic patients, 301 (38.4%) patients had poor sleep quality, and 124 (15.8%) were at high risk for 
OSA. Patients at increased risk for OSA were more obese; they also had higher blood pressure, fasting plasma insulin 
levels, insulin resistance assessed by homeostasis model assessment (HOMA-IR), and serum triglycerides levels (p < 
0.05). The frequency of risk for OSA was higher among obese patients compared with non-obese patients (34.8% vs. 
9.4%, p < 0.05). Logistic regression analysis revealed that male sex and bone mass index were independent predictors of 
risk for OSA. 
Conclusions: SD was prevalent among type 2 diabetic patients, and OSA could aggravate their risk for cardiovascular 
disease. Clinical treatment of these patients should include evaluation and intervention for SD.
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INTRODUCTION
Sleep disorder (SD) is a common chronic illness 
characterized by repetitive episodes of partial or complete 
cessation of breathing during sleep, which may affect up to 
17% of middle-aged adults [1]. Chronic sleep fragmentation, 
sleep deprivation, and intermittent nocturnal hypoxemia 
associated with SD have been implicated in metabolic 
dysfunction, including altered glucose metabolism and 
adverse cardiovascular complications [2,3]. Common 
antecedent risks such as obesity, hypertension, endothelial 
dysfunction, inflammatory state, and oxidative stress 
appear among patients with diabetes mellitus and patients 
with SD. The association between diabetes mellitus and 
SD and its precise mechanism are not well understood. 
It is likely that chronic intermittent hypoxia and sleep 
fragmentation lead to pathogenic factors such as increased 
sympathetic activity, dysregulation of the hypothalamus-
pituitary-adrenal axis, and activation of inflammatory 
pathways, resulting in abnormal glucose metabolism. 
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Large population studies have shown that SD is an 
independent risk factor for hypertension, cardiovascular 
disease (CVD) [4-8], and impaired glucose metabolism 
[9]. Self-reported history of snoring, a common symptom 
of SD, is independently associated with impaired glucose 
tolerance and type 2 diabetes mellitus (T2DM) [10,11]. 
Cross-sectional estimates from population studies have 
suggested that up to 40% of patients with obstructive sleep 
apnea (OSA) have T2DM [12,13]. Among patients who are 
known to have T2DM, the prevalence of OSA may be up 
to 23% [14], and the prevalence of some form of SD may 
be as high as 58% [15]. However, scanty documentation 
is available about the prevalence of SD among Asians. 
A community study of SD among middle-aged Chinese 
men and women in Hong Kong revealed 9% and 3.7% 
prevalence rates for SD and 4% and 2.1% for symptomatic 
OSA [16,17]. Because only limited studies have focused on 
the prevalence of SD in T2DM, especially among Asians, 
the goal of this study was to estimate the prevalence of 
SD among Korean diabetic patients and determine the 




We consecutively recruited 784 patients with T2DM 
who attended the outpatient department of endocrinology 
at Ewha Womans University Hospital from January 2008 
through December 2008. None of these patients used 
insulin injection or medications that would affect sleep, 
and none had serum creatinine levels greater than 1.4 mg/
dL, serum transaminases levels more than three times 
the upper limit of normal value, severe painful peripheral 
neuropathy, and alcohol dependency. The Institutional 
Review Board of Ewha Womans University Mokdong 
Hospital approved this study. Written informed consent 
was obtained from each subject. Degree of obesity was 
classified based on the results of an Asia-Pacific study [18]: 
non-obese patients had a body mass index (BMI) < 25 kg/
m
2 and obese patients had a BMI ≥ 25 kg/m
2. 
Survey assessment of sleep quality and risk for 
obstructive sleep apnea 
Sleep quality was assessed using a self-administered 
questionnaire. The Pittsburgh Sleep Quality Index 
(SQI) was used to evaluate sleep quality, and the Berlin 
Questionnaire (BQ) was used to evaluate risk for OSA. 
The SQI assesses sleep quality over the preceding month 
and differentiates ‘good’ sleepers from ‘poor’ sleepers 
[19]. Questionnaire responses involve seven components; 
each component is scored from 0 to 3, where a score of 3 
represents the negative extreme. Component scores are 
summed to provide the SQI global score (range, 0 to 21); 
scores > 5 identify ‘poor’ sleepers [19]. 
The BQ includes five items on snoring (category 1, items 
1-5), three items on daytime somnolence (category 2, items 
6-8), and one item on the history of hypertension (category 
3, item 9). The questionnaire also includes information 
about age, gender, height, and weight [20]. The overall 
score is based on the patient’s responses to each of the 
three categories. The snoring or daytime somnolence 
categories are positive if responses indicate persistent 
symptoms (> 3 to 4 times a week) on the questionnaire 
items. A positive score for the third category requires a 
history of hypertension or a BMI ≥ 25 kg/m
2. High risk for 
OSA is defined as a positive score for two or more of the 
three categories [21].
Anthropometric measurements and baseline 
sampling
The height and weight of each patient was measured, 
and BMI was calculated as body weight in kilograms 
divided by the square of height in meters (kg/m
2). Blood 
pressure (BP) was measured once for each patient in the 
supine position with a mercury sphygmomanometer; 
systolic BP and diastolic BP were measured to the nearest 
2 mmHg at Korotkoff sounds I and IV, respectively. 
Venous blood was drawn from each patient after 
an overnight fast to obtain baseline measurements of 
glucose, HbA1c, total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides (TG). Plasma 
glucose was measured using the glucose oxidase method 
(Beckman Model Glucose Analyzer 2, Brea, CA, USA). 
Total cholesterol (TC), HDL-C, and TG were measured 
by enzymatic methods using a Hitachi 7150 autoanalyzer 
(Hitachi, Tokyo, Japan). LDL cholesterol (LDL-C) was 
calculated as follows: TC (mg/dL) - HDL-C (mg/dL) - TG/5 
(mg/dL). 
Statistical analysis
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using SPSS version 16 (SPSS Inc., Chicago, IL, USA). The 
normality of distributions of the variables was analyzed 
using the Kolmogorov-Smirnov test. Data are expressed 
as means ± SD. Because TG and HDL-C exhibited skewed 
distribution, p values were based on logarithmic data, but 
mean values for untransformed data are presented.
Continuous variables were compared between subjects 
at high risk and those at low risk for OSA using an inde-
pendent t test and analysis of covariance (ANCOVA). The 
χ
2 test was used to assess differences in the frequency of 
sleep disturbance in each age group and sex. A logistic re-
gression analysis was performed to determine which vari-
ables predicted high risk for OSA. All p values were two-
tailed, and statistical significance was defined as p < 0.05.
RESULTS
Table 1 lists the clinical and biochemical characteristics 
of all participants. The mean age was 54 ± 12 years, and 
395 (50.4%) participants were male. The mean BMI value 
was 24.8 ± 3.3 kg/m
2, mean duration of diabetes was 9 ± 7 
years, and mean baseline HbA1c was 7.5 ± 1.4%. 
SQI results revealed poor sleep quality (PSQ) in 301 
(38.4%) of 784 diabetic patients, 132 (16.8%) of the 395 
male patients, and 169 (21.6%) of the 389 female patients. 
No significant differences were observed by sex. BQ 
identified 124 (15.8%) of the 784 patients (44 [5.6%] 
of the 389 female patients and 80 [10.2%] of the 394 
male patients) as being at high risk for OSA, revealing a 
significantly greater risk among male than female patients 
(p < 0.05).
Fig. 1 presents the frequency of PSQ by age and sex. PSQ 
frequency increased for patients aged up to their 50s: 3% 
in patients in their 30s, 8.1% in patients in their 40s, and 
17.2% in patients in their 50s; it then decreased to 13.3% 
in patients in their 60s and 8.4% in patients in their 70s 
and older. The frequency of PSQ in patients in their 40s 
and older was significantly higher than that in patients 
in their 30s for both sexes (p < 0.05). Similarly, the risk 
for OSA increased for patients aged up to their 50s: 4.9% 
in patients in their 30s, 12% in patients in their 40s, and 
Table 1. Characteristics of 748 patients with type 2 
diabetes
Characteristics Values







2 24.8 ± 3.3
< 25  
≥ 25  
337 (44.5)
420 (55.5)
Mean duration of diabetes, yr   9 ± 7
Systolic BP, mmHg 128 ± 15
Diastolic BP, mmHg   75 ± 10
HbA1c, %   7.5 ± 1.4
Fasting plasma glucose, mg/dL 132 ± 48
Total cholesterol, mg/dL 173 ± 36
HDL-C, mg/dL   51 ± 14
LDL-C, mg/dL   95 ± 35
Triglycerides, mg/dL   142 ± 142
Values are presented as mean ± SD or number (%).
BMI, body mass index; BP, blood pressure; HDL-C, high-density 
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.
Figure 1. Frequency of poor sleep quality by the Pittsburgh 
Sleep Quality Index (PSQI) according to age and sex.
Figure 2. Frequency of high risk for obstructive sleep apnea 
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16.1% in their 50s; it then decreased to 11.6% in patients 
in their 60s and 5.4% in patients in their 70s and older 
(Fig. 2). The frequency of risk for OSA was significantly 
higher among patients in their 40s, 50s, and 60s than 
among those in their 30s (p < 0.05). The frequency of risk 
for OSA was significantly higher for males than females 
among patients in their 40s (17.4% vs. 6.6%, p < 0.05) and 
in their 50s (21.5% vs. 10.7%, p < 0.05) (Fig. 2). Patients at   
high risk for OSA had higher BMI, systolic and diastolic 
blood pressure, fasting plasma insulin, insulin resistance 
assessed by homeostasis model assessment (HOMA-IR), 
and triglyceride levels compared with those at low risk 
(Table 2). Significant differences appeared between the 
two groups in systolic and diastolic blood pressure and 
triglyceride levels after adjusting for BMI. 
The frequency of risk for OSA was significantly higher 
among obese patients compared with non-obese patients 
(34.8% vs. 9.4%, p < 0.05). Logistic regression analysis 
revealed that male sex (odds ratio [OR], 3.14; confidence 
interval [CI], 1.26 to 7.83; p < 0.05) and BMI (OR, 1.25; CI, 
1.10 to 1.43; p < 0.01) were independent predictors of risk 
for OSA (Table 3).
DISCUSSION
This study found that SD was more prevalent in patients 
with T2DM than in the general population, in which it 
appears in approximately 9% of women and 24% of men 
[1]. Of 784 diabetic patients, 301 (38.4%) patients had poor 
sleep quality according to the SQI, and 124 (15.8%) were 
at high risk for OSA according to the BQ. Reports from 
the International Diabetes Federation (IDF) taskforce on 
epidemiology and prevention [22] have also revealed a high 
prevalence of SD among patients with T2DM, suggesting 
a prevalence of SD as high as 58% and a prevalence of 
OSA as high as 23%. Several prospective studies have 
reported an association between sleeping disorders and 
Table 3. Factors associated with the risk for obstructive sleep apnea by logistic regression analysis
Odds ratio 95% confidence interval p value
Male 3.14 1.26-7.83 0.014
BMI 1.25 1.10-1.43 0.001
Systolic BP 1.02 0.99-1.05 0.258
Diastolic BP 1.01 0.96-1.06 0.775
FPI 1.05 0.96-1.14 0.273
HOMA-IR 1.02 0.83-1.25 0.872
Triglyceride 1.00 0.99-1.00 0.797
Regression model included age, sex, BMI, systolic and diastolic pressure, HbA1C, FPI, HOMA-IR, triglyceride, and total, HDL, and LDL 
cholesterol.
BMI, body mass index; BP, blood pressure; FPI, fasting plasma insulin; HOMA-IR, insulin resistance assessed by homeostasis model 
assessment; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein. 
Table 2. Comparison of diabetic patients according to 
risk for OSA
High risk for OSA
(n = 124)
Low risk for OSA
(n = 660)
Mean age, yr  55 ± 11   55 ± 13
Mean BMI, kg/m
2 27.1 ± 3.5  24.4 ± 3.2
a
Systolic BP, mmHg 134 ± 15     127 ± 15
a,b
Diastolic BP, mmHg 79 ± 9     75 ± 10
a,b
HbA1c, %    7.5 ± 1.2   7.5 ± 1.4
FPI, μU/mL    18.1 ± 19.7      9 ± 6.7
a
HOMA-IR    6.9 ± 10.7      3 ± 2.7
a
FPG, mg/dL 134 ± 44 132 ± 49
Total cholesterol, mg/dL 173 ± 49 173 ± 33
HDL-C, mg/dL  49 ± 12   51 ± 14
LDL-C, mg/dL  93 ± 24    96 ± 37
Triglycerides, mg/dL 195 ± 97    132 ± 80
a,b
OSA, obstructive sleep apnea; BMI, body mass index; BP, 
blood pressure; FPI, fasting plasma insulin; HOMA-IR, insulin 
resistance assessed by homeostasis model assessment; 
FPG, fasting plasma glucose; HDL-C, high-density lipoprotein 
cholesterol; LDC-C, low-density lipoprotein cholesterol.
ap < 0.05 vs. high risk.
bp < 0.05 after adjustment for BMI.Shim U, et al. Sleep disorder in type 2 diabetes mellitus    281
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the development of diabetes. Total sleep duration is known 
to be an independent risk factor for developing diabetes. 
The Nurses’ Health Study, which examined sleep duration 
and diabetes, reported an increased risk of symptomatic 
incident diabetes over 10 years among those reporting 
sleep durations of 5 hours or less, even after controlling for 
many covariates [23]. A cross-sectional study of sleeping 
disorders among patients with T2DM using SQI reported 
that 48% of T2DM patients had poor sleep quality, and the 
poorest sleep quality was among patients who had been 
diagnosed more than 10 years earlier [24]. Many biological 
mechanisms have been proposed to explain how SD may 
lead to T2DM. One is the activation of the sympathetic 
nervous system, which plays a central role in the regulation 
of glucose and fat metabolism [25]. Repeated arousal 
from sleep after each obstructive breath exacerbates this 
effect [22]. Elevated cortisol levels [26], pro-inflammatory 
cytokines, and ghrelin levels may predispose an individual 
to insulin resistance, and decreased leptin levels may be 
the mechanism for increased prevalence of T2DM in SD 
[27].
Our results indicate that individuals at higher risk for 
OSA were more obese and had higher BP, fasting insulin 
levels, HOMA-IR, and triglyceride levels, suggesting 
that SD was associated with risk factors for CVD. Many 
prospective and cross-sectional studies have reported a 
link among OSA, CVD, and mortality [28-32]. Young et al. 
[33] reported that severe SD was associated with a three-
fold increase in all-cause mortality compared with an 
absence of SD based on an 18-year follow-up prospective 
cohort study. Studies on the prevalence of CVD and OSA 
have reported that 50% of SD patients are hypertensive 
and that 11-37% experience heart failure [34]. One 
cross-sectional study reported that OSA was associated 
with a range of CVD manifestations such as stroke, 
heart failure, and ischemic heart disease [8]. There are 
several explanations for the development of CVD among 
patients with OSA. Patients with OSA exhibit repetitive 
hypoxemia, CO2 retention, consequent sympathetic 
activation, and marked blood pressure elevation during 
sleep [29]; additionally, adverse changes in the circulating 
levels of many vasoactive or inflammatory mediators 
including nitric oxide, interleukin-6, tumor necrosis factor, 
and c-reactive protein, as well as platelet activation and 
coagulation factors promote the development of CVD [35-
39]. 
Our results revealed that obese diabetic patients 
are at higher risk for OSA, and logistic regression also 
demonstrated that BMI is an independent predictor of 
risk for OSA. A recent study of obese men (BMI ≥ 30 kg/
m
2) without major medical illnesses found that 60% of 
these men met the criteria for SD, and 27% had OSA [2]. 
The risk of having moderate to severe OSA over a 4-year 
period increases six-fold among individuals who gain 10% 
excess weight [40], suggesting that the high incidence of 
CV morbidity among patients with OSA is explained by 
the presence of obesity [41,42]. With the onset of OSA, 
individuals develop leptin resistance, which in turn 
contributes to further weight gain [28]. Inflammatory 
cytokines tumor necrosis factor (TNF)-α and interleukin 
(IL)-6, which are associated with daytime sleepiness, 
might also be involved in the causal pathway because they 
are elevated among obese patients with OSA [43]. 
Fasting plasma insulin levels and HOMA-IR were 
higher among patients at high risk for OSA. The 
mechanism underlying the relationship between SD 
and insulin resistance can be explained as follows [44]. 
Hypoxia and hypercapnia caused by sleep-disordered 
breathing provoke sympathetic nervous activity, releasing 
epinephrine, norepinephrine, and cortisol [45-47]. 
Sympathetic hyperactivity and increased catecholamine 
impair glucose homeostasis and induce insulin resistance 
by increasing glycogenolysis and gluconeogenesis [48,49]. 
Repetitive cycles of intermittent hypoxemia followed by re-
oxygenation may trigger the formation of reactive oxygen 
species, eliciting the release of inflammatory cytokines 
such as TNF-α and IL-6 [50,51]. Inflammatory cytokines 
play an important role in mediating peripheral insulin 
resistance by inhibiting glucose uptake by fat and muscle, 
increasing the level of counter-regulatory hormones and 
inducing the release of free fatty acids [52,53]. 
We found a higher frequency of risk for OSA among 
men, with logistic regression analysis revealing male sex to 
be an independent predictor. The higher prevalence of risk 
for OSA among men than women could be related to the 
greater tendency toward android fat distribution [54] and 
differences in upper airway muscle function during sleep 
[54]. Men have a greater increase in airway resistance and 
greater susceptibility to flow limitation during non-rapid 
eye movement (NREM) sleep than women do. During 
NREM sleep, women have a functional advantage over 
men that is protective against airway collapse, and this 282    The Korean journal of Internal Medicine Vol. 26, No. 3, September 2011
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protective mechanism is lost with the transition to REM 
sleep [54].
This study had several limitations. First, its relatively 
small sample size limits the generalization of results. 
Large-scale long-term research will be needed in the 
future. Second, we did not consider the medications used 
by patients or the effects of hypoglycemia. We excluded 
patients who used insulin injection or medications that 
might affect sleep, but we did not consider hypoglycemic 
events, which might affect sleep patterns. Finally, the 
results might be affected by recall bias and the subjective 
nature of self-reported snoring and OSA. However, self-
reported snoring and snoring reported by roommates 
were reasonably correlated in previous studies [55].
 In conclusion, our data suggest that SD is prevalent 
among type 2 diabetic patients and that individuals at high 
risk for OSA are also at higher risk for CVD. OSA appears 
to aggravate the risk of CVD among type 2 diabetic 
patients. Therefore, early detection and treatment of SD 
among type 2 diabetic patients is essential to modulate the 
relationship between SD and risk for CVD. 
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